GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Median PS Value

Scancell Holdings (FRA:SCP) Median PS Value : €0.00 (As of May. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Scancell Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2023 was €0. Scancell Holdings's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is €0.00.

As of today (2024-05-20), Scancell Holdings's share price is €0.096. Scancell Holdings's Median PS Value is €0.00. Therefore, Scancell Holdings's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Scancell Holdings's Median PS Value or its related term are showing as below:

FRA:SCP's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.7
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Scancell Holdings Median PS Value Historical Data

The historical data trend for Scancell Holdings's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Median PS Value Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scancell Holdings's Median PS Value

For the Biotechnology subindustry, Scancell Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Price-to-Median-PS-Value falls into.



Scancell Holdings Median PS Value Calculation

Scancell Holdings's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Scancell Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2023 was €0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (FRA:SCP) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Scancell Holdings's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.096/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings Median PS Value Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines